Archive of past Lupus Mechanisms and Targets Award (LMTA)
2020 Funded Grants
IgA-containing immune complexes in SLE
Jessica A. Hamerman, PhD
Benaroya Research Institute at Virginia Mason
Dynamic regulation of signaling pathways in SLE
Alessandra Pernis, MD
The Hospital for Special Surgery
Candidate pathobiont in lupus: genomic variation and pathogenesis
Gregg J Silverman, MD
New York University School of Medicine
Redesigning Dnase1L3 for the treatment of systemic lupus erythematosus
Roger Bryan Sutton, PhD
Texas Tech University Health Sciences Center
2019 Funded Grants
Targeting the inactive X for correcting dosage imbalances in lupus
Montserrat Anguera, PhD
University of Pennsylvania
Intrinsic B cell epigenetic mediators as therapeutic targets in lupus
Paolo Casali, MD
University of Texas Health Science Center at San Antonio
Targeting follicular helper T cell metabolism in lupus
Hongbo Chi, PhD
St. Jude Children's Research Hospital, Memphis, Tennessee
Cytokine immunoregulatory strategy to target SLE autoreactive B cells
Hui-Chen Hsu, PhD
University of Alabama at Birmingham
Ptprz: A therapeutic target for Lupus Nephritis
Vicki Kelley, PhD
Brigham and Women's Hospital, Inc.
2018 Funded Grants
Targeting follicular helper T cells in lupus
Joseph Craft, MD
Yale School of Medicine
The cyclic GAMP pathway in SLE
Keith Elkon, MD
University of Washington
Targeting interferon-stimulated transcription as a novel lupus therapy
David Levy, PhD
NYU School of Medicine
PTPN22 Function in Human B Cells and Inhibition to Reset Tolerance in SLE
Eric Meffre, PhD
Yale School of Medicine
Targeting peripheral T cell-B cell interactions in SLE
Deepak Rao, MD, PhD
Brigham and Women's Hospital
Targeting the CXCR3 chemokine axis in cutaneous lupus
Jillian Richmond, PhD
University of Massachusetts Medical School
Mammalian free glycan, glycocalyx and anti-glycan antibody in lupus
Nan Yan, PhD
University of Texas Southwestern Medical Center
2017 Funded Grants
The role of bacterial infections in the pathogenesis of lupus
Roberto Caricchio, MD
Temple University
Targeting the inactive X chromosome in lupus
Laura Carrel, PhD
The Pennsylvania State University College of Medicine
Characterization of STING SAVI gain of function mutations in mice
Katherine Fitzgerald, PhD
University of Massachusetts Medical School
ALCAM in Lupus
Chandra Mohan, MD, PhD
University of Houston
Defining new targets in lupus through identification of non-coding SNPs
Peter A. Nigrovic, MD
Brigham and Women's Hospital, Inc
Targeting endogenous glomerular repair in lupus nephritis
Janos Peti-Peterdi, MD, PhD
USC University of Southern California
Finding druggable pathways affected by the R90H-NCF1 SLE risk variants
Betty Tsao, PhD
Medical University of South Carolina
2016 Funded Grants
The role of TLR8 in lupus nephritis
Anne Davidson, MBBS
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Feinstein Institutes for Medical Research
Dissecting the effector function of pathogenic Tfh cells in human lupus
Rong Fan, PhD
Yale University
BRISC DUB activity as a novel target for lupus
Roger Greenberg, MD, PhD
University of Pennsylvania
A novel target for neutrophil NETosis in lupus skin inflammation
Ming-Lin Liu, MD, PhD
University of Pennsylvania Health System
Therapeutic inhibitors of antigen presentation pathways in SLE
Mark J. Mamula, PhD
Yale University
Targeting Follicular Helper CD4 T cells in SLE
Laurence Morel, PhD
University of Florida College of Medicine
TLR9 regulates Axl dependent migration of autoreactive B cells
Kerstin Nundel, PhD
University of Massachusetts Medical School
2014 Funded Grants
Investigating the mechanisms of lupus-associated CNS dysfunction
Michael Carroll, PhD
Children's Hospital Boston
Characterization and function of CD4 T cell subsets in lupus
Joseph Craft, PhD
Yale University
The contribution of epigenetics to SLE phenotype and outcome
Lindsey Ann Criswell, MD, MPH
National Institute of Arthritis and Musculoskeletal and Skin Diseases
The cyclic GAMP pathway in SLE
Keith Elkon, MD
University of Washington
Understanding the MoA of low dose IL-2 as a potential therapy for SLE
Charles Fathman, MD
Stanford University
IL-2 and IL-33 as therapeutic agents for lupus nephritis
Shu Man Fu, MD, PhD
The University of Virginia
Regulation of T follicular helper cells in SLE by E3 ubiquitin ligase Cbl-b
Wael Jarjour, MD
The Ohio State University
Estrogen-dependent microRNAs as potential targets for the treatment of SLE
Caroline Jefferies, PhD
Cedars-Sinai Medical Center
Role for SHP2 as a therapeutic target for systemic lupus erythematosus
Maria Kontaridis, PhD
Beth Israel Deaconess Medical Center
Sex and microbiota influence on immunoregulation and disease in BWF1 mice
Michele Kosiewicz, PhD
University of Louisville School of Medicine
Protein S: at the crossroads of thrombosis and inflammation in SLE
Carla Rothlin, PhD
Yale University
Therapeutic targeting of FcgRIIb on B cells in SLE
William Stohl, MD, PhD
University of Southern California, Keck School of Medicine
Targeting IL-10 producing B cells in SLE
Betty Tsao, PhD
Medical University of South Carolina
Role of Tim-1 in kidneys during lupus
Sheng Xiao, PhD
Brigham and Women's Hospital
Glycans and glycosylation defects as novel targets in lupus
Nan Yan, PhD
UT Southwestern Medical Center
2013 Funded Grants
Influence of BANK1 in the in vivo development of lupus
Marta Alarcon- Riquelme, MD, PhD
Fundacion Publica Andaluza Progreso Y Salud
B cell histone modifications and non-coding RNA as targets in lupus therapy
Paolo Casali, MD
University of Texas Health Science Center
Aggregated MAVS as a disease mechanism in SLE
Phillip Cohen, MD
Temple University
Role of the BAFF receptor BCMA to control B cell homeostasis and tolerance
Loren D. Erickson, PhD
University of Virginia
Towards understanding the role of NCF2 in SLE
Chaim Oscar Jacob, MD
University of Southern California, Keck School of Medicine
Targeting a dendritic cell-stromal axis in lupus
Theresa T. Lu, MD, PhD
The Hospital for Special Surgery
Bradykinins in lupus
Chandra Mohan, MD, PhD
University of Houston
High through-put screening to repurpose drugs for lupus therapies
Laurence Morel, PhD
University of Florida College of Medicine
Targeting interferogenic signals regulated by SLE risk gene PTPN22
Erik Jon Peterson, MD
University of Minnesota Medical School
Metabolism of effector T cells as a target in SLE
Jeffrey C. Rathmell, PhD
Vanderbilt University School of Medicine
IRF1 decoy treatment
Kathleen Sullivan, MD, PhD
The Children's Hospital of Philadelphia
Identifying functional variants that underlie SLE susceptibility
Edward K. Wakeland, PhD
UT Southwestern Medical Center
2012 Funded Grants
Inhibition of IL-6 trans-signaling in SLE
Anne Davidson, MBBS
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell and Feinstein Institutes for Medical Research
TREM-1 in lupus nephritis
Laurie Davis, PhD
UT Southwestern Medical Center
The CR2:C3d receptor: ligand interaction as a therapeutic target in lupus
Michael Holers, MD
University of Colorado Denver, AMC and DC
New targets for treatment of glucocorticoid-resistant lupus
Michael Karin, PhD
University of California, San Diego
Immunoproteasome selective inhibitors for lupus treatment
Gang Lin, PhD
Weill Cornell Medical College
CD4 T cell metabolism in SLE: characterization and target identification
Laurence Morel, PhD
University of Florida College of Medicine
Targeting DNA polynucleotides in lupus
Fred Perrino, PhD
Wake Forest School of Medicine
The roles of the individual elements of the BAFF axis in murine SLE
William Stohl, MD, PhD
University of Southern California, Keck School of Medicine
The role of immune complexes and BAFF in promoting atherosclerosis in lupus
Barbara Vilen, PhD
The University of North Carolina at Chapel Hill